Replies to post #191150 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Most of us anticipate that the treatment patients will fare better than the control patients. The P1 trials indicated that the treatment patients had a mOS of somewhere like 30, 34 or 36 months (I'd have to look it up and so I'm estimating - but I know it was AT LEAST 30 mo) and the control had a mOS of 18 months. I think that's why they thought they would get a large separation between the arms.

However, it does seem like there are some control patients that are living longer than had been anticipated. And Kat, from the Kat's Cure story, is an example of a patient who had recurred, and then been given DCVax-L, and is now seemingly doing extremely well and her GBM is in remission.

Her story from ASCO is cited below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141495644

So will there be such a separation as that (18 to 30/36?)? Maybe not. But also remember... there were a little less than half the control patient that did not cross over to treatment. So it's extremely likely that those patients will bring down that control curve.

[Rootjim]

j e d a true control never crossed over to DCVax-L. Most or all true controls in DCVax-L have evented. DCVax- L trial is getting superior results compared to SOC. Simple as that and why the interest in DCVax-L. IMO